IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
Share price
+$2.13 (+149.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IRONWOOD PHARMACEUTICALS INC grew revenue 26.2% to $389.32M over the twelve months to Jun 30, 2026. Operating income rose 219.3% to $234.17M, moving the operating margin from 23.8% to 60.1%. Free cash flow was $127.01M, up 22.8% from a year earlier.
Revenue
$389.32M
+26.2% vs. a year earlier
Operating income
$234.17M
+219.3% vs. a year earlier
Free cash flow
$127.01M
+22.8% vs. a year earlier
EPS, diluted
$0.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $595.16M
- P/E ratio
- 4.6
- Price to sales
- 1.53
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 21.34%
Fundamentals
- Revenue
- $389.32M
- Net income
- $129.87M
- EPS, diluted
- $0.77
- Free cash flow
- $127.01M
- Book value per share
- -$0.97
- Diluted shares
- 167M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$389.32M+26.2% YoY
Gross profit
–
Operating income
$234.17M+219.3% YoY
Net income
$129.87M
EPS, diluted
$0.77
Free cash flow
–
Reported periodTrailing twelve months